The Lithuanian Biotechnology Association joins EuropaBio: it’s time to put Lithuania on a map of the most biotech savvy nations
Brussels, 28 April 2021 – EuropaBio is pleased to announce that the Lithuanian Biotechnology Association (LBTA) has joined the National Association Council (NAC).
The LBTA has 29 industry and academic members and has a focus on life sciences, health technologies and bioeconomics. It has the mission to build on an existing established economic foundation from biotechnology, with national activities including vaccine manufacture. As part of the EuropaBio NAC, LBTA will feature in the May 10 NAC Summit ‘Building on biotechnology: From vaccines to economic growth for Europe’, discussing how Europe must build from the advances in policy, funding and collaboration during Covid, to enable continued economic growth from biotech.
EuropaBio Director-General Dr. Claire Skentelbery says “LBTA really demonstrates how all European countries play a critical role in delivering biotechnology as an economic and societal contributor. We are delighted to bring their expertise into the National Associations Council and look forward to the NAC Summit on May 10”.
Agne Vaitkeviciene, Executive Director of the LBTA added ”Lithuania is pioneering in genome editing technologies [CRIPSR-CAs9] that has immense potential in the DNA/RNA vaccine development. In addition, we have immense scientific expertise in the field related to emerging non-viral vaccine technology. Faster recovery from pandemics calls for collaboration and Lithuania is ready to share its biotech potential and to contribute to production and development of life-saving biotech products.
Download the full PRESS RELEASE below.